SEATTLE, WA--(Marketwired - August 21, 2013) - Atossa Genetics Inc.
) and its subsidiary The National Reference Laboratory for Breast Health (NRLBH)
, will display their products and services at the Georgia Obstetrical and Gynecological Society 2013 Annual Meeting
, August 22-25, in Greensboro, Georgia, and at the inaugural National Women's Survivors Convention
, August 22-24, in Nashville, Tennessee.
The ForeCYTE Breast Health Test, provided by the NRLBH, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a sample of nipple aspirate fluid collected with Atossa's hand-held, FDA Class II medical device which is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about Atossa's device, click here: https://vimeo.com/62365818.
"The ForeCYTE Breast Health Test serves as an early warning system for the detection of precancerous cellular abnormalities that heighten a woman's breast cancer risk," said Chris Destro, Vice President of Sales and Marketing. "This is particularly true for younger women for whom little is done today in terms of risk assessment or screening unless there is a specific reason for concern, such as a strong family history. We believe the ForeCYTE Breast Health Test empowers all women with vital information that they and their doctors can use to take charge of their breast health and make more informed treatment decisions."
Mr. Destro continued, "We are excited to work with outstanding organizations like the Women Survivors Alliance, which provide vital services to breast cancer victims. In times of trouble women need to come together, share information and feel the support of other women as they cope with their disease and their new normal. As we continue to roll out the ForeCYTE test nationally, we believe we will have a significant impact on the incidence of this dreaded disease so that in the future fewer women will be afflicted. We look forward to meeting with physicians, patients and other breast health stakeholders at these important conferences."
Atossa's specimen collection devices are available through physicians nationwide.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the NRLBH, patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information on Atossa, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.